论文部分内容阅读
目的探讨水飞蓟宾联合软肝丸治疗血吸虫病肝纤维化的疗效、机制及安全性。方法将200例血吸虫病肝纤维化患者随机分为对照组和治疗组,每组100例,分别采用水飞蓟宾(对照组)、水飞蓟宾联合软肝丸口服(治疗组),于治疗3、6、9个月和12个月,比较观察2组患者的临床效果。结果治疗12个月后,患者5项临床症状治疗组明显减轻,总有效率均达75%以上,均显著高于对照组。肝脏B超分级治疗组与对照组比较,3、6个月时无改善(P均>0.05),9、12个月时,治疗组好于对照组(P均<0.05)。治疗组治疗3、6个月时均无改善(P均>0.05),9、12个月时较6个月时有改善(P均<0.05)。血清肝纤维化四项,治疗3个月时,治疗组与对照组差异无统计学意义(P>0.05);6、9、12个月时,差异均有统计学意义(P均<0.05);治疗组治疗3、6个月时比较,差异无统计学意义(P>0.05),9、12个月时均低于6个月时(P均<0.05)。治疗过程中未出现明显不良反应。结论水飞蓟宾联合软肝丸有较好的抗血吸虫病肝纤维化的作用。
Objective To investigate the curative effect, mechanism and safety of silybin combined with Ruangan Pill on schistosomiasis with hepatic fibrosis. Methods 200 cases of schistosomiasis patients with liver fibrosis were randomly divided into control group and treatment group, with 100 cases in each group. The patients were treated with silybin (control group), silibinin combined with Ruangan Wan (treatment group) Treatment for 3, 6, 9 months and 12 months, the clinical effects of two groups were compared. Results After 12 months of treatment, the five clinical symptoms of patients in the treatment group were significantly reduced, the total effective rate reached 75%, were significantly higher than the control group. Compared with the control group, no significant improvement was found at 3 and 6 months (all P> 0.05). At 9 and 12 months, the treatment group was better than the control group (all P <0.05). The treatment group had no improvement at 3 and 6 months (all P> 0.05), and improved at 9 and 12 months (P <0.05) compared with 6 months. There was no significant difference between the treatment group and the control group (P> 0.05), and there were significant differences at 6, 9 and 12 months (all P <0.05) . There was no significant difference in the treatment group between 3 and 6 months (P> 0.05). The mean time of treatment group was lower than 6 months at 9 and 12 months (all P <0.05). No obvious adverse reactions occurred during the treatment. Conclusion Silybin combined with Ruangan Pill has a good anti-schistosomiasis effect on hepatic fibrosis.